Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1978 Jul;14(1):1–5. doi: 10.1128/aac.14.1.1

In Vitro Activity and Beta-Lactamase Stability of BL-S786 Compared with Those of Other Cephalosporins

Nalinee Aswapokee 1, Prasit Aswapokee 1, Kwung P Fu 1, Harold C Neu 1
PMCID: PMC352396  PMID: 686701

Abstract

In vitro activity of BL-S786, a new parenterally semisynthetic cephalosporin, was investigated against 570 bacterial isolates. BL-S786 inhibited most Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella. It inhibited some Enterobacter and indole-positive Proteus, but it was less active against these later species than was cefamandole, cefuroxime, or cefoxitin. It was not active against Serratia marcescens, Pseudomonas aeruginosa, or Bacteroides fragilis. BL-S786 was the least active new cephalosporin tested against staphylococci and was less active than cephalothin against streptococcal species. The activity of BL-S786 was not altered by the type of assay medium nor by 50% serum. The size of the test inoculum altered the minimal inhibitory and bactericidal concentrations for inhibition of some organisms, particularly those with Richmond type I β-lactamases. BL-S786 was not hydrolyzed by the R-factor-mediated, Richmond type III β-lactamase, but it was hydrolyzed by type I β-lactamases.

Full text

PDF
2

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Jones R. N., Fuchs P. C., Gavan T. L., Gerlach E. H., Barry A., Thornsberry C. BL-S786, a new parenteral cephalosporin. I. A collaborative in vitro susceptibility comparison to cephalothin against 5,762 clinical bacterial isolates. J Antibiot (Tokyo) 1977 Jul;30(7):576–582. doi: 10.7164/antibiotics.30.576. [DOI] [PubMed] [Google Scholar]
  2. Jones R. N., Thornsberry C., Barry A. L., Fuchs P. C., Gavin T. L., Gerlach E. H. BL-S786, a new parenteral cephalosporin. II. In vitro antimicrobial activity comparison with six related cephalosporins. J Antibiot (Tokyo) 1977 Jul;30(7):583–592. doi: 10.7164/antibiotics.30.583. [DOI] [PubMed] [Google Scholar]
  3. Leitner F., Misiek M., Pursiano T. A., Buck R. E., Chisholm D. R., DeRegis R. G., Tsai Y. H., Price K. E. Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity. Antimicrob Agents Chemother. 1976 Sep;10(3):426–435. doi: 10.1128/aac.10.3.426. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Neu H. C. Cefamandole, a cephalosporin antibiotic with an unusually wide spectrum of activity. Antimicrob Agents Chemother. 1974 Aug;6(2):177–182. doi: 10.1128/aac.6.2.177. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Neu H. C. Cefoxitin, a semisynthetic cephamycin antibiotic: antibacterial spectrum and resistance to hydrolysis by gram-negative beta-lactamases. Antimicrob Agents Chemother. 1974 Aug;6(2):170–176. doi: 10.1128/aac.6.2.170. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. O'Callaghan C. H., Morris A., Kirby S. M., Shingler A. H. Novel method for detection of beta-lactamases by using a chromogenic cephalosporin substrate. Antimicrob Agents Chemother. 1972 Apr;1(4):283–288. doi: 10.1128/aac.1.4.283. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. O'Callaghan C. H., Sykes R. B., Griffiths A., Thornton J. E. Cefuroxime, a new cephalosporin antibiotic: activity in vitro. Antimicrob Agents Chemother. 1976 Mar;9(3):511–519. doi: 10.1128/aac.9.3.511. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Richmond M. H., Sykes R. B. The beta-lactamases of gram-negative bacteria and their possible physiological role. Adv Microb Physiol. 1973;9:31–88. doi: 10.1016/s0065-2911(08)60376-8. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES